检索结果-南通市图书馆

The Adverse Event Profile in Patients Treated with Transferon<sup>TM</sup>(dialyzable Leukocyte Extracts): A Preliminary Report

引用

Pharmacology & Pharmacy 2015年第2期6卷 65-74页

作者： Toni Homberg Violeta Sáenz Jorge Galicia-Carreón Iván Lara Edgar Cervantes-Trujano Maria C. Andaluz erika Vera Oscar Pineda Julio Ayala-Balboa Alejandro Estrada-García Sergio Estrada-Parra Mayra Pérez-Tapia Maria C. Jiménez-Martínez Clinical Trials Branch and Clinical Immunology Service Unit of External Services and Clinical Research (USEIC) National School of Biological Sciences National Polytechnic Institute Mexico City Mexico Unit of Pharmacovigilance Unit of External Services and Clinical Research (USEIC) National School of Biological Sciences National Polytechnic Institute Mexico City Mexico Department of Immunology National School of Biological Sciences National Polytechnic Institute Mexico City Mexico Unit of R&D in Bioprocesses (UdiBI) National School of Biological Sciences National Poly-technic Institute Mexico City Mexico Department of Biochemistry Faculty of Medicine National Autonomous University of Mexico Mexico City Mexico

Background: dialyzable leukocyte extracts (DLE) are heterogeneous mixtures of peptides less than 10 kDa in size that are used as immunomodulatory adjuvants in immune-mediated diseases. TransferonTM is DLE manufactured by National Polytechnic Institute (IPN), and is registered by Mexican health-regulatory authorities as an immunomodulatory drug and commercialized nationally. The proposed mechanism of action of TransferonTM is induction of a Th1 immunoregulatory response. Despite that it is widely used, to date there are no reports of adverse events related to the clinical safety of human DLE or TransferonTM. Objective: To assess the safety of TransferonTM in a large group of patients exposed to DLE as adjuvant treatment. Methods: We included in this study 3844 patients from our Clinical Immunology Service at the Unit of External Services and Clinical Research (USEIC), IPN. Analysis was performed from January 2014 to November 2014, searching for clinical adverse events in patients with immune-mediated diseases and treated with TransferonTM as an adjuvant. Results: In this work we observed clinical nonserious adverse events (AE) in 1.9% of patients treated with TransferonTM (MD 1.9, IQR 1.7 - 2.0). AE were 2.8 times more frequently observed in female than in male patients. The most common AE were headache in 15.7%, followed by rash in 11.4%, increased disease-related symptomatology in 10%, rhinorrhea in 7.1%, cough in 5.7%, and fatigue in 5.7% of patients with AE. 63% of adverse event presentation occurred from day 1 to day 4 of treatment with TransferonTM, and mean time resolution of adverse events was 14 days. In 23 cases, the therapy was stopped because of adverse events and no serious adverse events were observed in this study. Conclusion: TransferonTM induced low frequency of nonserious adverse events during adjuvant treatment. Further monitoring is advisable for different age and disease groups of patients.

关键词： dialyzable Leukocyte Extracts Adverse Events Monitoring Drug Safety Adjuvant Therapy Immunoregulation Guidelines Transfer Factor Pharmacovigilance

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

含有光活性衍生物的水处理剂

引用

水处理信息报导 2008年第6期 42-42页

作者： Kalman, erika

根据本发明，该水处理组成物是一种有效抑制腐蚀和生物腐蚀过程的组成物。作为一种缓蚀剂，其含有一种或多种氨基和／或羟甲基化单或聚合磷酸，其作为缓蚀剂显示出系统效应，可以是羟甲基化氨基酸、嘌呤衍生物、不饱和芳香剂和碳酸，稠... 详细信息

根据本发明，该水处理组成物是一种有效抑制腐蚀和生物腐蚀过程的组成物。作为一种缓蚀剂，其含有一种或多种氨基和／或羟甲基化单或聚合磷酸，其作为缓蚀剂显示出系统效应，可以是羟甲基化氨基酸、嘌呤衍生物、不饱和芳香剂和碳酸，稠芳香化合物（苯和甲基苯三唑衍生物）、水溶性聚合物和无机磷酸盐衍生物，作为生物缓蚀剂，

关键词：嘌呤衍生物水处理剂光活性水溶性聚合物无机磷酸盐腐蚀过程羟甲基化三唑衍生物

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

A Pilot Trial Testing the Feasibility of Using Molecular-Guided Therapy in Patients with Recurrent Neuroblastoma

引用

Journal of Cancer Therapy 2012年第5期3卷 602-612页

作者： Giselle L. Saulnier Sholler William Ferguson Genevieve Bergendahl erika Currier Shannon R. Lenox Jeffrey Bond Marni Slavik William Roberts Deanna Mitchell Don Eslin Jacqueline Kraveka Joel Kaplan Nehal Parikh Suman Malempati Gina Hanna Emily Eugster David Cherba Jeremy Miller Craig Webb Cardinal Glennon Children’s Hospital Saint Louis University School of Medicine St. Louis University St. Louis USA Center for Cancer Genomics and Computational Biology Pediatric Oncology Translational Research Program at the Van Andel Research Institute in Grand Rapids Grand Rapids USA Center for Children’s Cancer and Blood disorders Arnold Palmer Hospital for Children MD Anderson Cancer Center Orlando Orlando USA Department of Pediatric Oncology Helen DeVos Children’s Hospital Michigan State University Grand Rapids USA Department of Pediatric Oncology Oregon Health Science University Portland USA division of Hematology/Oncology 2J Connecticut Children’s Medical Center Hartford USA Pediatric Hematology/Oncology Medical University of South Carolina Charleston USA Pediatric Oncology Levine Children’s Hospital Charlotte USA Rady Children’s Hospital San diego University of California San Diego School of Medicine at the University of California San Diego San Diego USA Vermont Cancer Center Department of Medicine University of Vermont Burlington USA

Background: Neuroblastoma is the most common extracranial solid tumor in children, and treatment options for recurrent neuroblastoma are limited. Using molecular profiling to target the molecular vulnerabilities of neuroblastoma with existing therapeutic agents may result in a rational, data-driven approach with potential to improve clinical outcomes. Methods: The primary objective of this pilot study was to evaluate the feasibility of supporting real-time treatment decisions through predictive modeling of genome-wide mRNA gene expression data from neuroblastoma tumor biopsies. Feasibility was defined as completion of tumor biopsy, histopathological evaluation, RNA extraction and quality control, gene expression profiling within a CLIA-certified laboratory, bioinformatic analysis, generation of a drug predicttion report, molecular tumor board review yielding a formulated treatment plan, and independent medical monitor review within a 2-week period. Results: Five patients with multiply relapsed or refractory neuroblastoma were enrolled between April and June 2010. All biopsies passed histopathology and RNA quality control. Generation of gene expression data and its analysis (3-7 days), reports which linked this data into medically actionable drug candidates (1-5 days), molecular tumor board (1-3 days) and independent medical monitor review (1 day) were all completed in real-time. The average time was 10.5 days for all patients. Conclusion: This study shows that it is feasible to create therapeutic treatment plans based on genomic profiling in less than 12 days. This warrants further testing in a Phase I study to determine safety of predicted treatments and evaluate whether the information obtained in these analyses would result in patient benefit.

关键词： Neuroblastoma Molecular Guided Therapy Predictive Therapies Molecular Profiling Genomic Profiling Pediatric Cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中意高校摄影邀请展作品选登

引用

海峡影艺 2020年第1期 65-72页

作者：姚璐李砚辞柳笛宫哲张辉孙铭鑫郭政昊欧均宜矫健谢爱军 erika Pellicci bonomelli giulia Lonoce Isadora Mltikafe dianadidi 中央美术学院西安理工大学中国美术学院西安美术学院佛罗伦萨国立美术学院米兰布雷拉美院都灵美院

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

*** of a novel anti-angiogenic protein for the treatment of exudative age-related macular degeneration

引用

Annals of Eye Science 2018年第1期 429-429页

作者： erika Hooker Natalija Popovic Andrea Barabino Anthony Flamier Gilbert Bernier Bruno Larrivée Department of Biochemistry Maisonneuve-Rosemont Hospital Research CentreUniversity of MontrealMontrealQuebecCanada Department of Ophthalmology Maisonneuve-Rosemont Hospital Research CentreUniversity of MontrealMontrealQuebecCanada

Background:Age-related macular degeneration(AMD)is a leading cause of blindness in *** exudative(wet)form of AMD accounts for approximately 15%of AMD patients,but is responsible for the majority of severe vision loss associated with the *** AMD is characterized by choroidal neovascularization,the abnormal growth of blood vessels from the choroid into the sub-retinal *** therapies for exudative AMD directly target and inhibit the vascular endothelial growth factor(VEGF)signaling pathway,a signaling axis that promotes endothelial cell *** initially effective at restoring visual acuity,recent studies suggest that chronic use of anti-VEGF therapies can lead to further vision impairment through off-target effects on photoreceptors and other non-vascular *** off-target effects of anti-VEGF therapy highlights the need for alternative treatments for this increasingly common *** have recently identified a novel anti-angiogenic protein,AAP1 that inhibits retinal angiogenesis during *** a regulator of the vasculature,our current work aims to characterize the function of AAP1 in endothelial cells and determine the potential of AAP1 as a therapy for exudative ***:To address our aims,we used various in vivo and in vitro models of normal and pathological vascular *** were injected intravitreally with AAP1 to investigate its effects on developmental and pathological *** HUVECs,we employed immunofluorescent quantifications to determine the impact of AAP1 on sprouting angiogenesis by measuring cellular proliferation,apoptosis and *** investigate the signaling events that mediate the actions of AAP1,we examined key signaling pathways involved in angiogenesis by western blotting and ***:We evaluated the role of AAP1 as a regulator of angiogenesis during retinal development and mouse models of *** pilot data show that AAP1 prevents angiogenesis in vitro and in vivo,and th

关键词： Age-related macular degeneration(AMD) angiogenesis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

毕达哥拉斯博物馆

引用

建筑实践 2017年第15期 16-23页

作者： OBR Paolo Brescia and Tommaso Principi(Architecture) erika Skabar(Landscape) Favero & Milan Ingegneria S.p.A.(Engineering) Claudia La Monarca(Safe and Security) Giovanni Panizon(External Exhibits)

该项目在全球和地方水平上有双重的目的:一方面它推进城市的发展,提升克罗托内作为文化旅游目的地的地位,另一方面激活城市和社会的更新进程。博物馆的建造设计旨在创造一个与地形紧密结合的新景观,设计通过延续山体的趋势将博物馆与景... 详细信息

该项目在全球和地方水平上有双重的目的:一方面它推进城市的发展,提升克罗托内作为文化旅游目的地的地位,另一方面激活城市和社会的更新进程。博物馆的建造设计旨在创造一个与地形紧密结合的新景观,设计通过延续山体的趋势将博物馆与景观融为一体,同时突出了山体的形象。建筑和景观的关系在室内通过框定室外景色的前厅空间和咖啡餐厅被突显出来,感觉就像用望远镜看东西。博物馆可

关键词：博物馆克罗托内

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Envita’s Precision Cancer Care: 35-Fold Improvement in Response Rates

引用

Journal of Cancer Therapy 2024年第4期15卷 99-120页

作者： Sheba Goklany John C. Oertle III Ronald Matthias Jr. Daniel Warren David Medina Rory Sears Robert Zieve Kendra Quart Christopher Aussems Jon Moma Shannon Miller Zach Poteet Conner Coffin Courtney Middleton erika Ware Phylicia Zarnosky Julie Nowak Winlove Suasin Daniel Conway Chad Burk Ruth Tan-Lim dino Prato Envita Medical Centers Scottsdale AZ USA

New clinical approaches are imperative beyond the widely adopted National Comprehensive Cancer Network (NCCN) guidelines, utilized by prominent cancer institutions. Cancer is the leading cause of death among individuals younger than 85 years within the United States. Despite significant technological advances, including the expenditure of hundreds of billions, treatment outcomes and overall survival have not notably improved for most types of advanced cancer over the last several decades. Over the past 24 years, Envita Medical Centers has pioneered a unique form of personalized treatment approach for late-stage and refractory cancer patients, introducing groundbreaking innovations in the field. Our integrated algorithm utilizes advanced genomics, transcriptomics, and highly tailored immunotherapy, resulting in remarkable outcome improvements. This study presents Envita’s innovative personalized treatment algorithms and examines the response outcomes of 199 late-stage cancer patients treated at Envita Medical Centers over a two-year period. Compared to standard of care and palliative chemotherapy, Envita’s treatment demonstrated a remarkable 35-fold improvement in overall response rates (Figure 1). Moreover, 88% of the patients, the majority presenting with Stage 3 or 4 cancer, experienced a 43-fold improvement in quality of life with minimal side effects, as compared to standard of care chemotherapy and palliative care. This revolutionary success is attributed to Envita’s personalized therapeutic algorithms, which incorporate customized immunotherapy. Envita’s precision care approach has also achieved a 100% better response rate compared to over 65 global chemotherapy clinical trials with more than 2700 patients. The results from this study suggest that a wider utilization of Envita’s personalized approach can significantly benefit patients with late-stage and refractory cancer.

关键词： Envita Medical Centers Late-stage Cancer Overall Response Rate Quality of Life Circulating Tumor Cells (CTCs) Mutant Allele Frequency (MAF) Precision Care

来源：

维普期刊数据库评论